A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients

Neuroscience Research

Volumn 46, Issue 3, 2003, Pages 299-307

  Toyooka, Kazuhiko ^a,b   Watanabe, Yuichiro ^a,b   Iritani, Shuji ^c   Shimizu, Eiji ^d   Iyo, Masaomi ^d   Nakamura, Ryosuke ^c   Asama, Koue ^e   Makifuchi, Takao ^f   Kakita, Akiyoshi ^a   Takahashi, Hitoshi ^a   Someya, Toshiyuki ^b   Nawa, Hiroyuki ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Ohjima Hospital   (Japan)

^f National Saigata Medical Center   (Japan)

Author keywords

Cytokine; IL 1; IL 1RA; Inflammation; Postmortem brain; Prefrontal cortex; Schizophrenia

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOSPIPRAMINE; HALOPERIDOL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LEVOMEPROMAZINE; MESSENGER RNA; OXYPERTINE; PERICIAZINE; PIPAMPERONE; RISPERIDONE; THIORIDAZINE; ZOTEPINE;

ADULT; AGED; ARTICLE; BRAIN REGION; BRAIN TISSUE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; MALE; MENTAL PATIENT; PARIETAL LOBE; PATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0038510909     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-0102(03)00093-2     Document Type: Article

References (41)

1. Akiyama K. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res. 37:1999;97-106.
2. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry. 4:1999;182-188.
3. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 20:1996;199-203.
4. Berkenbosch F., van Oers J., del Rey A., Tilders F., Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science. 238:1987;524-526.
5. Bitter I., Volavka J., Scheurer J. The concept of the neuroleptic threshold: an update. J. Clin. Psychopharmacol. 11:1991;28-33.
6. Dunn A.J., Wang J. Cytokine effects on CNS biogenic amines. Neuroimmunomodulation. 2:1995;319-328.
7. Ericsson A., Liu C., Hart R.P., Sawchenko P.E. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 361:1995;681-698.
8. Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., Someya T., Kakita A., Takahashi H., Nawa H. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol. Psychiatry. 7:2002;673-682.
9. Ganguli R., Rabin B.S., Kelly R.H., Lyte M., Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. New York Acad. Sci. 496:1987;676-685.
10. Horai R., Asano M., Sudo K., Kanuka H., Suzuki M., Nishihara M., Takahashi M., Iwakura Y. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187:1998;1463-1475.
11. Ilyin S.E., Gayle D., Flynn M.C., Plata-Salaman C.R. Interleukin-1beta system (ligand, receptor type I, receptor accessory protein and receptor antagonist), TNF-alpha, TGF-beta1 and neuropeptide Y mRNAs in specific brain regions during bacterial LPS-induced anorexia. Brain Res. Bull. 45:1998;507-515.
12. Imai C., Sugai T., Iritani S., Niizato K., Nakamura R., Makifuchi T., Kakita A., Takahashi H., Nawa H. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci. Lett. 305:2001;185-188.
13. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
14. Katila H., Hanninen K., Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry. 4:1999;179-181.
15. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry. 150:1993;1408-1410.
16. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:1996;39-50.
17. Maruta E., Yabuuchi K., Nishiyori A., Takami S., Minami M., Satoh M. B2-adrenoceptors on the glial cells mediate the induction of interleukin-1β mRNA in the rat brain. Mol. Brain Res. 49:1997;291-294.
18. Minami M., Kuraishi Y., Yabuuchi K., Yamazaki A., Satoh M. Induction of interleukin-1β mRNA in rat brain after transient forebrain ischemia. J. Neurochem. 58:1992;390-392.
19. Muller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;1-33.
20. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., Ulmschneider M., Engel R.R., Moller H.J., Schwarz M.J. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry. 159:2002;1029-1034.
21. Nawa H., Takahashi M., Patterson P.H. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol. Psychiatry. 5:2000;594-603.
22. O'Callaghan E., Sham P., Takei N., Glover G., Murray R.M. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet. 337:1991;1248-1250.
23. O'Callaghan E., Gibson T., Colohan H.A., Buckley P., Walshe D.G., Larkin C., Waddington J.L. Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. Br. Med. J. 305:1992;1256-1259.
24. Owen B.M., Eccleston D., Ferrier I.N., Young A.H. Raised levels of plasma interleukin-1β in major and postviral depression. Acta Psychiatr. Scand. 103:2001;226-228.
25. Prolo P., Licinio J. Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol. Psychiatry. 4:1999;109-111.
26. Radewicz K., Garey L.J., Gentleman S.M., Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59:2000;137-150.
27. Sapolsky R., Rivier C., Yamamoto G., Plotsky P., Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science. 238:1987;522-524.
28. Segman R.H., Meltzer A., Gross-Tsur V., Kosov A., Frisch A., Inbar E., Darvasi A., Levy S., Goltser T., Weizman A., Galili-Weisstub E. Preferential transmission of interleukin-1 receptor antagonist alleles in attention deficit hyperactivity disorder. Mol. Psychiatry. 7:2002;72-74.
29. Shintani F., Kanba S., Nakaki T., Nibuya M., Kinoshita N., Suzuki E., Yagi G., Kato R., Asai M. Interleukin-1β augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothalamus. J. Neurosci. 13:1993;3574-3581.
30. Shintani F., Nakaki T., Kanba S., Sato K., Yagi G., Shiozawa M., Aiso S., Kato R., Asai M. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J. Neurosci. 15:1995;1961-1970.
31. Smith D.E., Renshaw B.R., Ketchem R.R., Kubin M., Garka K.E., Sims J.E. Four new members expand the interleukin-1 superfamily. J. Biol. Chem. 275:2000;1169-1175.
32. Song C., Lin A., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 42:2000;157-164.
33. Stern A.S., Pan Y.C., Hellmann R.S., Parker K.P., Mueller D., Hulmes J.D., Kilian P.L., Chizzonite R. Purification of homogeneity and amino acid sequence analysis of a receptor protein for interleukin 1. Arch. Biochem. Biophys. 274:1989;26-36.
34. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1β and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 215:1996;201-204.
35. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Immobilization stress increases mRNA levels of interleukin-1 receptor antagonist in various rat brain regions. Cell. Mol. Neurobiol. 17:1997;557-562.
36. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry. 5:2000;293-300.
37. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110:2002;249-257.
38. Vereker E., O'Donnell E., Lynch M.A. The inhibitory effect of interleukin-1β on long-term potentiation is coupled with increased activity of stress-activated protein kinases. J. Neurosci. 20:2000;6811-6819.
39. Wong M.L., Licinio J. Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation. 1:1994;110-115.
40. Xu H.M., Wei J., Hemmings G.P. Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. Br. J. Psychiatry. 164:1994;251-253.
41. Yabuuchi K., Minami M., Katsumata S., Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Mol. Brain Res. 27:1994;27-36.